0ELV Stock Overview
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Guerbet SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €34.57 |
| 52 Week High | €35.50 |
| 52 Week Low | €15.70 |
| Beta | 0.75 |
| 1 Month Change | -2.61% |
| 3 Month Change | 83.90% |
| 1 Year Change | 109.03% |
| 3 Year Change | -0.97% |
| 5 Year Change | -36.97% |
| Change since IPO | 10.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0ELV | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 5.7% | 2.0% | 2.7% |
| 1Y | 109.0% | -8.5% | 0.3% |
Return vs Industry: 0ELV exceeded the UK Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: 0ELV exceeded the UK Market which returned 0.3% over the past year.
Price Volatility
| 0ELV volatility | |
|---|---|
| 0ELV Average Weekly Movement | 7.2% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0ELV's share price has been volatile over the past 3 months.
Volatility Over Time: 0ELV's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 2,920 | David Hale | www.guerbet.com |
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services.
Guerbet SA Fundamentals Summary
| 0ELV fundamental statistics | |
|---|---|
| Market cap | €443.37m |
| Earnings (TTM) | €23.87m |
| Revenue (TTM) | €795.65m |
18.6x
P/E Ratio0.6x
P/S RatioIs 0ELV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0ELV income statement (TTM) | |
|---|---|
| Revenue | €795.65m |
| Cost of Revenue | €206.19m |
| Gross Profit | €589.47m |
| Other Expenses | €565.60m |
| Earnings | €23.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 25, 2024
| Earnings per share (EPS) | 1.90 |
| Gross Margin | 74.09% |
| Net Profit Margin | 3.00% |
| Debt/Equity Ratio | 96.4% |
How did 0ELV perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield26%
Payout RatioDoes 0ELV pay a reliable dividends?
See 0ELV dividend history and benchmarks| Guerbet dividend dates | |
|---|---|
| Ex Dividend Date | Jul 01 2024 |
| Dividend Pay Date | Jul 03 2024 |
| Days until Ex dividend | 68 days |
| Days until Dividend pay date | 70 days |
Does 0ELV pay a reliable dividends?
See 0ELV dividend history and benchmarks